Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

ClinicalTrials.gov ID: NCT02554786

Public ClinicalTrials.gov record NCT02554786. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

Study identification

NCT ID
NCT02554786
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
2,216 participants

Conditions and interventions

Conditions

Interventions

  • Indacaterol acetate/Mometasone furoate Drug
  • Mometasone furoate Drug
  • Salmeterol xinafoate/fluticasone propionate Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2015
Primary completion
Nov 20, 2018
Completion
Jun 27, 2019
Last update posted
Mar 4, 2020

2015 – 2019

United States locations

U.S. sites
29
U.S. states
17
U.S. cities
29
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35244
Novartis Investigative Site Los Angeles California 90025
Novartis Investigative Site Orange California 92868
Novartis Investigative Site Riverside California 92506
Novartis Investigative Site San Diego California 92117
Novartis Investigative Site San Jose California 95117
Novartis Investigative Site Stockton California 95207
Novartis Investigative Site Westminster California 92683
Novartis Investigative Site Denver Colorado 80230
Novartis Investigative Site Miami Florida 33144
Novartis Investigative Site Tallahassee Florida 32308
Novartis Investigative Site Winter Park Florida 32789
Novartis Investigative Site Baltimore Maryland 21236
Novartis Investigative Site Waldorf Maryland 20602
Novartis Investigative Site North Dartmouth Massachusetts 02747-3322
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Bellevue Nebraska 68123
Novartis Investigative Site Las Vegas Nevada 89119
Novartis Investigative Site Skillman New Jersey 08558
Novartis Investigative Site Cortland New York 13045
Novartis Investigative Site Oklahoma City Oklahoma 73120
Novartis Investigative Site Tulsa Oklahoma 74136
Novartis Investigative Site Medford Oregon 97504
Novartis Investigative Site Portland Oregon 97213
Novartis Investigative Site Pittsburgh Pennsylvania 15241
Novartis Investigative Site North Charleston South Carolina 29407
Novartis Investigative Site Boerne Texas 78006
Novartis Investigative Site El Paso Texas 79903
Novartis Investigative Site Greenfield Wisconsin 53228

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 359 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02554786, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 4, 2020 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02554786 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →